top of page
Radiofrequency Ablation of Cervical Thyroid Cancer Metastases—Experience of Endocrinology Practices in the United States
Radiofrequency Ablation of Cervical Thyroid Cancer Metastases—Experience of Endocrinology Practices in the United States
Citation
Ahmad, Shahzad, et al. “Radiofrequency Ablation of Cervical Thyroid Cancer Metastases—Experience of Endocrinology Practices in the United States.” Journal of the Endocrine Society, vol. 7, no. 7, June 2023, p. bvad066. DOI.org (Crossref), https://doi.org/10.1210/jendso/bvad066.
URL
Abstract
Radiofrequency ablation (RFA) is used in the United States to treat benign thyroid nodules; however, experience with treating cervical recurrence/persistence of papillary thyroid cancer (PTC) is limited.
Objective
To evaluate the efficacy RFA for the treatment of cervical recurrence/persistence of PTC in the United States.
Although it is well recognized that surgery is the treatment of choice for recurrent thyroid cancer in the neck, some patients are not surgical candidates, or may not want to undergo repeat surgeries after their initial resection. While active surveillance is an option for selected patients, many patients have anxiety with this approach and may choose intervention despite no progression in tumor kinetics or size [30, 31]. RFA is emerging as an alternative option for these patients.
RFA is minimally invasive and has a lower complication rate than surgery; however, use in recurrent cervical PTC recurrence is still limited in the United States [12-14, 17]. The results of our study are illustrative of the real-world outpatient application and results using this technique.
Technical success has traditionally been defined as a 50% volume reduction in the thermal ablation literature with regards to benign thyroid nodules; however, in case of malignancy, treatment should be with curative intent. Therefore, we have defined complete success as a 100% volume reduction that mimics the results after surgery, and have recognized that a near-complete response of 90% volume reduction is likely to be clinically similar to a complete response, as the remaining tissue may not be viable or may have only microscopic disease that can be monitored. This is further supported by the low post procedure Tg levels in these patients.
Conclusion
RFA is a safe and effective treatment option for metastatic cervical lymph node recurrences of PTC in carefully selected patients with thyroid cancer. It is particularly suitable for those not deemed candidates for further surgery or who decline further surgical intervention.
Key Words
radiofrequency ablation, thyroid cancer, recurrence, persistent disease
Contact Us
Address
2320 N. Third Street
Phoenix, AZ 85004
Contact
tel: 602-889-2923
fax: 602-889-2925 / 602-889-2926
Opening Hours
Mon - Thurs
7:30 am – 4:30 pm
Friday
7:30 am – 4:00 pm
Closed M-F
12:00 - 1:00 pm Lunch
bottom of page